Tara Vrooman Murante

Assistant Professor

Ye J, Qin SS, Hughson AL, Hannon G, Vrooman TG, Lesch ML, Eckl SL, Benoodt L, Mills BN, Lord EM, Belt BA, Linehan DC, Luheshi N, Eyles J, Gerber SA. Blockade of LIF and PD-L1 Enhances Chemotherapy in Preclinical PDAC Models. Cancers (Basel). 2025 Jan 9;17(2):204. doi: 10.3390/cancers17020204.

Hughson AL, Hannon G, Salama NA, Vrooman TG, Stockwell CA, Mills BN, Garrett-Larsen J, Qiu H, Katerji R, Benoodt L, Johnston CJ, Murphy JD, Kruger E, Ye J, Gavras NW, Keeley DC, Qin SS, Lesch ML, Muhitch JB, Love TMT, Calvi LM, Lord EM, Luheshi N, Elyes J, Linehan DC, Gerber SA. Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer. Mol Ther Nucleic Acids. 2024 Sep 30;35(4):102350. doi: 10.1016/j.omtn.2024.102350. eCollection 2024 Dec 10.

Ye J, Gavras NW, Keeley DC, Hughson AL, Hannon G, Vrooman TG, Lesch ML, Johnston CJ, Lord EM, Belt BA, Linehan DC, Eyles J, Gerber SA. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models. J Immunother Cancer. 2023 May;11(5):e006842. doi: 10.1136/jitc-2023-006842.

Ye J, Mills BN, Qin SS, Garrett-Larsen J, Murphy JD, Uccello TP, Han BJ, Vrooman TG, Johnston CJ, Lord EM, Belt BA, Linehan DC, Gerber SA. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer. J Immunother Cancer. 2022 Jul;10(7):e004784. doi: 10.1136/jitc-2022-004784.